Anika Therapeutics (ANIK) Free Cash Flow (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Free Cash Flow data on file, last reported at -$4.9 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 675.47% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was $93000.0, a 98.09% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, down 8.44% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$4.9 million, down from -$2.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for ANIK reached as high as $11.1 million in Q3 2025 and fell as low as -$7.0 million in Q2 2023.
• Historically, Free Cash Flow has averaged -$356882.4 across 5 years, with a median of -$748000.0 in 2024.
• Across the five-year window, Free Cash Flow soared 321.72% in 2022 and tumbled 675.47% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$6.9 million in 2022, then jumped by 126.07% to $1.8 million in 2023, then sank by 40.99% to $1.1 million in 2024, then plunged by 302.92% to -$2.2 million in 2025, then plunged by 127.64% to -$4.9 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$4.9 million in Q1 2026, -$2.2 million in Q4 2025, and $11.1 million in Q3 2025.